Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.
- S. Harland, D. Newell, Z. Siddik, R. Chadwick, A. Calvert, K. Harrap
- Biology, MedicineCancer Research
- 1 April 1984
In vitro studies with plasma and urine demonstrated that, in contrast to cisplatin, CBDCA is a stable complex [t 1/2 - 37 degrees; plasma, 30 hr, and urine, 20 to 460 hr].
A potent antitumour quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice.
Changes in the deoxyribonucleoside triphosphate pools of mouse 5178Y lymphoma cells following exposure to methotrexate or 5-fluorouracil.
Changes are reported in the deoxyribonucleoside triphosphate pools of L5178Y cells during their exposure to methotrexate or 5-fluorouracil, accompanied by an increase in deoxycytidine triph phosphate concentration.
Studies with a mathematical model of folate metabolism.
ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer.
Biotransformation of the platinum drug JM216 following oral administration to cancer patients
The biotransformation profile following oral administration of JM216 shows a variety of Pt(IV) and Pt(II) metabolites in plasma that differ significantly from other systemically applied platinum drugs.
A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration
Clinical studies of divided dose schedules using doses within the range of pharmacokinetic linearity (≤120 mg/m2) are now being investigated and little nonhaematological toxicity was seen at doses associated with myelosuppression and antitumour activity.
Genomic imbalances associated with acquired resistance to platinum analogues.
Studies on the pharmacokinetics of chlorambucil and prednimustine in man.
- D. Newell, A. Calvert, K. Harrap, T. Mcelwain
- Biology, ChemistryBritish journal of clinical pharmacology
- 1 February 1983
Research aimed at producing chlorambucil analogues, which cannot be metabolised, seems justified, and the use of prednimustine in routine combination therapy is not recommended.